| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc408585f6863d7865c90ab9a4632135 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2002-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_878fd04fc090239a9cc94cb87d040592
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffd4cd53d4e7967de1a3cb0203815510
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78c5cad96eef8f79f4ddfc2cb92c7769 |
| publicationDate |
2003-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003060442-A1 |
| titleOfInvention |
In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| abstract |
The use of professional antigen presenting cells genetically modified to enhance expression of an immunostimulatory cytokine is disclosed for the treatment of individuals having tumors or infections. The genetically modified professional antigen presenting cells are injected directly at or near the site of the tumor or infection. Preferred professional antigen presenting cells include dendritic cells, and preferred immunostimulatory cytokines include interleukins such as IL-12. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7247444-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007269407-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014007669-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021034943-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014007667-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011217270-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004247578-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003219379-A1 |
| priorityDate |
1998-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |